Spirometry readings and blood biomarkers (inflammatory cells, levels of cortisol and salbutamol from reliever ... Synairgen, Teva, Theravance Biopharma and Verona Pharma. Disclaimer: AAAS and ...

Teva Pharmaceutical Industries Limited (TEVA)’s share was trading at $13.94 as of April 7th. TEVA’s trailing and forward P/E were 872 and 5.37 respectively according to Yahoo Finance. After ...

Teva Pharmaceutical Industries recently received FDA acceptance of its supplemental Biologics License Application to expand AJOVY®'s use for preventing migraines in pediatric patients, an ...

Below is Validea's guru fundamental report for TEVA PHARMACEUTICAL INDUSTRIES LTD (ADR) (TEVA). Of the 22 guru strategies we follow, TEVA rates highest using our Acquirer's Multiple Investor model ...

Teva Pharmaceutical (NYSE:TEVA) and South Korean generic drugmaker Samsung Bioepis announced Monday the U.S. commercial availability of Epysqli, a biosimilar drug targeting AstraZeneca’s (NASDAQ ...

We came across a bullish thesis on Teva Pharmaceutical Industries Limited (TEVA) on Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical ...

Teva and Samsung Bioepis are offering Epysqli, which is is a biosimilar to Alexion Pharmaceuticals' Soliris (eculizumab) for the treatment of paroxysmal nocturnal hemoglobinuria, atypical ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the ...

The management of Israeli pharma group Teva has laid out its strategy for a return to growth after a challenging few years, with a greater emphasis on innovative medicines and a focus on complex ...

Soliris® (eculizumab), making it one of the greatest cost-saving biosimilars to Soliris® in the U.S. Teva and Samsung Bioepis entered into a strategic partnership in January 2025 for the ...

Teva's announcement of the tentative settlement came amid its second-quarter results update, which revealed a 3% reduction in revenues to $3.8 billion compared to the same period of 2021, with a ...